Mounjaro and Hair Loss: What's Actually Happening to Your Hair

The medical term is telogen effluvium: a temporary shift in the hair growth cycle caused by physiological stress, including rapid weight loss.
Hair shedding typically begins 2–4 months after the triggering event and usually resolves on its own over several months.
Tirzepatide's SmPC and clinical trial data do not list hair loss as a common adverse effect of the medicine itself.
Nutritional adequacy (particularly protein and micronutrients) while losing weight matters for hair health, and is worth discussing with your prescriber.

Hair loss during Mounjaro treatment is real, and it worries a lot of people — but the cause is almost never the medicine itself. Most hair shedding reported on tirzepatide is a form of temporary stress-related hair loss triggered by rapid weight change, not a direct drug side effect. Here's what the evidence says, and how to think about it. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber reviews every consultation before any treatment is issued.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Understanding the hair-loss question so you can make a good decision about it

Is Mounjaro making your hair fall out, or is something else going on?

This is a question our prescribers hear most weeks, and it deserves a straight answer. The shedding people notice on Mounjaro is almost always telogen effluvium — a well-recognised pattern in which physiological stress pushes a higher proportion of hair follicles into the resting (telogen) phase at the same time. When those hairs shed two to four months later, the volume can be alarming. The trigger isn't the drug; it's the rapid change in body weight and, sometimes, reduced calorie intake.

This distinction matters. Telogen effluvium is self-limiting. Once the body adapts to its new weight and nutrition stabilises, the hair growth cycle resets and shedding slows. For most people this happens within six to nine months of the peak shed. How tirzepatide affects hair is a separate question from how weight loss does, and understanding the difference changes what you do next.

It is also worth knowing that the Mounjaro SmPC (the prescribing document regulators require manufacturers to maintain) does not list alopecia or hair loss as a common or uncommon adverse reaction. That doesn't make your experience less real; it means the pharmacological mechanism of tirzepatide is not the primary driver. The NHS medicines page for tirzepatide is a useful plain-English reference for the established side-effect profile.

The factors that actually shape how much hair you lose

Three things tend to determine whether someone loses noticeable hair during rapid weight loss: the speed of loss, the adequacy of protein intake, and individual genetic baseline.

Speed matters because a steep energy deficit is a stronger physiological stressor than a gradual one. GLP-1 and dual-agonist medicines like tirzepatide are effective precisely because they reduce appetite substantially, but that means some people eat far less than they realise, especially in the early months. Protein is the nutrient most consistently linked to hair health: hair shafts are almost entirely keratin, a protein, and follicle cells are among the fastest-dividing in the body. When overall intake drops sharply, follicles are not a priority tissue. There is also emerging interest in whether deficiencies in iron, zinc and biotin accelerate stress-related shedding, though evidence for supplementation in otherwise well-nourished adults is mixed. How tirzepatide changes your metabolism is worth reading alongside this, because understanding what's happening calorically helps you manage intake more consciously.

Individual genetic baseline is the third factor. People with a personal or family history of androgenetic alopecia (pattern baldness) may find that the telogen shed reveals underlying thinning that was progressing anyway. In those cases, the weight-loss episode accelerates something that was already happening, which is important to know, because it changes the management conversation.

What you can actually do about it

The most practical steps are nutritional. Prioritising adequate protein (aiming for enough to maintain muscle as well as support follicle function) is the single most evidence-consistent action. Specific targets depend on your body weight, activity level and the stage of treatment you're at; those numbers are a conversation for your prescriber or a dietitian, not a one-size rule.

Avoiding crash-level restriction matters too. If nausea on a dose increase has made eating very difficult, and that's been going on for several weeks, flagging it with your clinical team is worth doing, not just for hair but for muscle preservation and general wellbeing. Managing hair shedding while on Mounjaro covers practical strategies in more detail.

Standard hair-care advice also applies: gentle handling of wet hair, avoiding tight styles that add mechanical stress to already fragile shafts, and not combining aggressive heat styling with a period of systemic stress. These are not treatments for telogen effluvium, but they reduce additional breakage on top of the shed.

If shedding is severe, patchy rather than diffuse, accompanied by other symptoms (fatigue, feeling cold, irregular periods), or is not improving after nine or ten months, it is worth asking your GP to check thyroid function and iron stores. Those conditions can both cause hair loss and be aggravated by rapid weight change. Changes to hair texture on tirzepatide (a separate but related question) and the broader picture of hair loss reported on Mounjaro are explored further in our related guides. You can also read about the hair regrowth timeline once shedding slows.

If you're thinking about starting treatment and this is a concern, or you're already treating with Mounjaro and want to raise it, our prescribers are available to talk through the clinical picture. The free consultation is the right place to start, and if you want to understand how weight-loss treatment works more broadly before that, it's a good read. The MHRA's Yellow Card scheme is there if you wish to report any suspected side effect formally.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions